S&P 500   4,352.13 (-1.14%)
DOW   34,231.56 (-0.61%)
QQQ   359.69 (-1.33%)
AAPL   174.56 (-0.53%)
MSFT   320.71 (-0.02%)
META   297.44 (-0.74%)
GOOGL   131.18 (-1.91%)
AMZN   130.20 (-3.76%)
TSLA   256.81 (-2.20%)
NVDA   413.87 (-2.02%)
NIO   8.48 (-3.85%)
BABA   84.19 (-1.81%)
AMD   96.65 (-3.68%)
T   15.35 (-1.29%)
F   12.19 (-1.38%)
MU   68.31 (-1.97%)
CGC   0.77 (-11.53%)
GE   113.62 (-1.07%)
DIS   82.63 (+0.08%)
AMC   7.75 (-5.02%)
PFE   32.95 (-1.99%)
PYPL   58.80 (-3.38%)
NFLX   384.99 (-0.34%)
S&P 500   4,352.13 (-1.14%)
DOW   34,231.56 (-0.61%)
QQQ   359.69 (-1.33%)
AAPL   174.56 (-0.53%)
MSFT   320.71 (-0.02%)
META   297.44 (-0.74%)
GOOGL   131.18 (-1.91%)
AMZN   130.20 (-3.76%)
TSLA   256.81 (-2.20%)
NVDA   413.87 (-2.02%)
NIO   8.48 (-3.85%)
BABA   84.19 (-1.81%)
AMD   96.65 (-3.68%)
T   15.35 (-1.29%)
F   12.19 (-1.38%)
MU   68.31 (-1.97%)
CGC   0.77 (-11.53%)
GE   113.62 (-1.07%)
DIS   82.63 (+0.08%)
AMC   7.75 (-5.02%)
PFE   32.95 (-1.99%)
PYPL   58.80 (-3.38%)
NFLX   384.99 (-0.34%)
S&P 500   4,352.13 (-1.14%)
DOW   34,231.56 (-0.61%)
QQQ   359.69 (-1.33%)
AAPL   174.56 (-0.53%)
MSFT   320.71 (-0.02%)
META   297.44 (-0.74%)
GOOGL   131.18 (-1.91%)
AMZN   130.20 (-3.76%)
TSLA   256.81 (-2.20%)
NVDA   413.87 (-2.02%)
NIO   8.48 (-3.85%)
BABA   84.19 (-1.81%)
AMD   96.65 (-3.68%)
T   15.35 (-1.29%)
F   12.19 (-1.38%)
MU   68.31 (-1.97%)
CGC   0.77 (-11.53%)
GE   113.62 (-1.07%)
DIS   82.63 (+0.08%)
AMC   7.75 (-5.02%)
PFE   32.95 (-1.99%)
PYPL   58.80 (-3.38%)
NFLX   384.99 (-0.34%)
S&P 500   4,352.13 (-1.14%)
DOW   34,231.56 (-0.61%)
QQQ   359.69 (-1.33%)
AAPL   174.56 (-0.53%)
MSFT   320.71 (-0.02%)
META   297.44 (-0.74%)
GOOGL   131.18 (-1.91%)
AMZN   130.20 (-3.76%)
TSLA   256.81 (-2.20%)
NVDA   413.87 (-2.02%)
NIO   8.48 (-3.85%)
BABA   84.19 (-1.81%)
AMD   96.65 (-3.68%)
T   15.35 (-1.29%)
F   12.19 (-1.38%)
MU   68.31 (-1.97%)
CGC   0.77 (-11.53%)
GE   113.62 (-1.07%)
DIS   82.63 (+0.08%)
AMC   7.75 (-5.02%)
PFE   32.95 (-1.99%)
PYPL   58.80 (-3.38%)
NFLX   384.99 (-0.34%)
LON:HCM

HUTCHMED (HCM) Share Forecast, Price & News

GBX 253
-6.50 (-2.50%)
(As of 04:35 PM ET)
Compare
Today's Range
247
261.50
50-Day Range
193.60
259.50
52-Week Range
130
337.46
Volume
45,548 shs
Average Volume
54,621 shs
Market Capitalization
£2.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

HCM stock logo

About HUTCHMED (LON:HCM) Stock

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

HCM Price History

HCM Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
From Naval Flight Officer to CEO
First Female Founded, Publicly Traded, Space Company. Discover more
Bank of America Securities Sticks to Its Buy Rating for HUTCHMED (HCM)
Goldman Sachs Remains a Hold on HUTCHMED (HCM)
Hutchmed: Attractive Chinese R&D Giant
See More Headlines
Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
1,990
Year Founded
N/A

Profitability

Net Income
£-29,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£757.24 million
Cash Flow
GBX 101.41 per share
Book Value
GBX 92 per share

Miscellaneous

Free Float
N/A
Market Cap
£2.20 billion
Optionable
Not Optionable
Beta
0.87
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Chi Keung To ACGI (Age 71)
    B.Sc., BSc, M.B.A., MBA, Exec. Chairman
    Comp: $85k
  • Dr. Wei-Guo Su B.Sc. (Age 65)
    Ph.D., CEO, Chief Scientific Officer & Exec. Director
    Comp: $1.97M
  • Mr. Chig Fung Cheng BEc (Age 56)
    CA, CFO & Exec. Director
    Comp: $886k
  • Ms. Edith Shih BSE (Age 71)
    C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., MA, Company Sec. & Non-Exec. Director
  • Dr. Karen Jane Atkin (Age 57)
    Exec. VP & COO
  • Mr. Kin Hung Lee M.B.A. (Age 46)
    Sr. VP of Corp. Fin. & Devel.
  • Mr. Charles George Rupert Nixon (Age 53)
    Group Gen. Counsel
  • Ms. Selina Zhang
    Sr. VP of Global HR
  • Dr. Qingmei Wang Ph.D. (Age 60)
    Sr. VP of Bus. Devel. & Strategic Alliances
  • Mr. Hong Chen (Age 53)
    Sr. VP & Chief Commercial Officer- China













HCM Stock - Frequently Asked Questions

How have HCM shares performed in 2023?

HUTCHMED's stock was trading at GBX 264 at the beginning of the year. Since then, HCM shares have decreased by 4.2% and is now trading at GBX 253.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Intelsat (I), Associated British Foods (ABF), Fossil Group (FOSL), Chaarat Gold (CGH), AMC Entertainment (AMC), Bank of America (BAC), First Data (FDC), Air Canada (AC), Apollo Global Management (APO) and China Unicom (Hong Kong) (CHU).

What is HUTCHMED's stock symbol?

HUTCHMED trades on the London Stock Exchange (LON) under the ticker symbol "HCM."

How do I buy shares of HUTCHMED?

Shares of HCM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is HUTCHMED's stock price today?

One share of HCM stock can currently be purchased for approximately GBX 253.

How much money does HUTCHMED make?

HUTCHMED (LON:HCM) has a market capitalization of £2.20 billion and generates £757.24 million in revenue each year. The company earns £-29,420,000.00 in net income (profit) each year or GBX (0.04) on an earnings per share basis.

How many employees does HUTCHMED have?

The company employs 1,990 workers across the globe.

How can I contact HUTCHMED?

HUTCHMED's mailing address is Cheung Kong Center, 48th Floor 2 Queen's Road, Central, Hong Kong. The official website for the company is www.chi-med.com. The company can be reached via phone at +85221213888.

This page (LON:HCM) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -